Literature DB >> 9226141

Statistical inference for cost-effectiveness ratios.

E M Laska1, M Meisner, C Siegel.   

Abstract

Methods for statistical inference for cost-effectiveness (C/E) ratios for individual treatment and for incremental cost-effectiveness (delta C/ delta E) ratios when two treatments are compared are presented. In a lemma, we relate the relative magnitude of two C/E ratios to the delta C/ delta E ratio. We describe a statistical procedure to test for dominance, or admissibility, that can be used to eliminate an inferior treatment. The one-sided Bonferroni's confidence interval procedure is generalized to the two-sided case. The method requires only that two confidence intervals be available, one for cost and one for effectiveness. We describe Fieller-based confidence intervals and show them to be shorter than Bonferroni intervals. When distribution assumptions hold and variance and covariance estimates are available, Fieller intervals are preferable. However, Bonferroni intervals can be applied in more diverse situations and are easier to calculate. A simple Bonferroni based technique, and a likelihood ratio statistic given by Siegel, Laska and Meisner, for testing the null hypothesis that the C/E ratios of two treatments are equal is presented. The approaches are applied to the data from a phase II clinical trial of a new treatment for sepsis considered previously by others.

Entities:  

Mesh:

Year:  1997        PMID: 9226141     DOI: 10.1002/(sici)1099-1050(199705)6:3<229::aid-hec268>3.0.co;2-m

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  11 in total

Review 1.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis.

Authors:  J C Davis; C A Marra; M C Robertson; K M Khan; M Najafzadeh; M C Ashe; T Liu-Ambrose
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

4.  Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation.

Authors:  Sharon M Hall; James M Lightwood; Gary L Humfleet; Alan Bostrom; Victor I Reus; Ricardo Muñoz
Journal:  J Behav Health Serv Res       Date:  2005 Oct-Dec       Impact factor: 1.505

5.  Cost effectiveness of abciximab during routine medical practice.

Authors:  S O Reed; C D Mullins; L S Magder
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

6.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

7.  Individualized cost-effectiveness analysis.

Authors:  John P A Ioannidis; Alan M Garber
Journal:  PLoS Med       Date:  2011-07-12       Impact factor: 11.069

8.  The probability of cost-effectiveness.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  BMC Med Res Methodol       Date:  2002-03-11       Impact factor: 4.615

9.  Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial.

Authors:  Jennifer C Davis; Ging-Yuek Robin Hsiung; Stirling Bryan; John R Best; Janice J Eng; Michelle Munkacsy; Winnie Cheung; Bryan Chiu; Claudia Jacova; Philip Lee; Teresa Liu-Ambrose
Journal:  BMJ Open       Date:  2017-03-29       Impact factor: 2.692

10.  An economic evaluation of resistance training and aerobic training versus balance and toning exercises in older adults with mild cognitive impairment.

Authors:  Jennifer C Davis; Stirling Bryan; Carlo A Marra; Devika Sharma; Alison Chan; B Lynn Beattie; Peter Graf; Teresa Liu-Ambrose
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.